Previous 10 | Next 10 |
home / stock / invvy / invvy news
Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &...
Stocks in News: RDHL, ADXS RedHill's RHB-104 successful in late-stage Crohn's study; shares up 40% premarket Discussion : RedHill Biopharma’s ( RDHL ) RB-104 succeeds in Phase 3 clinical trial on Crohn's disease patients. Primary endpoint of remission at 26th week against the d...
SLOUGH, England , July 31, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) (Indivior or the Company) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied Dr. Reddy's Laboratories' (DRL's) motion for a stay of the July 13, 2018 preliminary injunction (PI...
CUPERTINO, Calif. , July 30, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for PERSERIS ™ (risperidone), which was ...
SLOUGH, England and RICHMOND, Va. , July 27, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved PERSERIS ™ , the first once-monthly subcutaneous risperidone-containing, long-acting injectable (LAI) fo...
INDIVIOR PLC ADR (INVVY) Q2 2018 Earnings Conference Call July 25, 2018 6:30 AM ET Executives Shaun Thaxter - Chief Executive Officer Javier Rodriguez - Chief Legal Officer Mark Crossley - Chief Financial Officer Analysts Christian Glennie - Stifel Financial Corp. Harry S...
The following slide deck was published by INDIVIOR PLC ADR in conjunction with their 2018 Q2 earnings Read more ...
NEW YORK, NY / ACCESSWIRE / July 25, 2018 / Indivior PLC (OTC PINK: INVVY ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 25, 2018 at 11:30:00 AM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investor...
Indivior PLC ADR ( OTCPK:INVVY ): Q2 EPS of $0.10 Revenue of $268M (-6.9% Y/Y) Press Release More news on: INDIVIOR PLC ADR, INDIVIOR PLC, Earnings news and commentary, Healthcare stocks news,
Noteworthy events during the week of July 22-28 for healthcare investors. More news on: Krystal Biotech, Axsome Therapeutics, Eisai Co., Ltd. ADR, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance PR Newswire RICHMOND, Va. , May 23, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation o...
Indivior Announces Q1 2024 Financial Results PR Newswire SLOUGH, United Kingdom and RICHMOND, Va. , April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024 . The earnings re...
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone PR Newswire This head-to-head pharmacodynamic study in healthy volunteers...